Di Zhe Pharmaceutical: DZD8586 obtained the approval notice of drug clinical trials from the State Food and Drug Administration

Di Zhe Pharmaceutical announced that DZD8586 obtained the approval notice of drug clinical trials from the State Drug Administration.

The chairman of the company is XIAOLIN ZHANG (Zhang Xiaolin). Mr. XIAOLIN ZHANG (Zhang Xiaolin), currently the chairman and general manager of the company, born in 1964, American nationality, postdoctoral degree in molecular genetics from cancer center of Harvard Medical School, visiting professor of institute of molecular medicine of Peking University. From July 1996 to June 1998, he was a researcher at the Center for Biomolecular Genetic Engineering at Boston University. From July 1998 to May 2006, he worked at the AstraZeneca R&D Center in Boston, where he served as a senior scientist and director. From June 2006 to December 2017, he established the China Innovation Center of AstraZeneca Investments (China) Co., Ltd. and served as the global vice president; In October 2017, he founded Di Zhe Limited, and from December 2017 to September 2020, he served as the director and chief executive officer of Di Zhe Limited; Since September 2020, he has served as the chairman and general manager of the issuer.

This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if you have any questions, please contact us.